Fluoroquinolone-resistant mutants of Burkholdena cepacia

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 3, 2008, Pages 1201-1203

  Pope, C F ^a   Gillespie, S H ^a   Pratten, J R ^b   McHugh, T D ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL SURVIVAL; BIOFILM; BURKHOLDERIA CEPACIA; GENE MUTATION; GROWTH RATE; GYRA GENE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PARC GENE; PRIORITY JOURNAL;

ANTI-INFECTIVE AGENTS; BIOFILMS; BURKHOLDERIA CEPACIA; CIPROFLOXACIN; COLONY COUNT, MICROBIAL; DESICCATION; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; WATER MICROBIOLOGY;

EID: 40549138069     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00799-07     Document Type: Article

References (27)

1. Bagel, S., V. Hullen, B. Wiedemann, and P. Heisig. 1999. Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli. Antimicrob. Agents Chemother. 43:868-875.
2. Beyer, R., E. Pestova, J. J. Millichap, V. Stosor, G. A. Noskin, and L. R. Peterson. 2000. A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux. Antimicrob. Agents Chemother. 44:798-801.
3. Billington, O. J., T. D. McHugh, and S. H. Gillespie. 1999. Physiological cost of rifampin resistance induced in vitro in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 43:1866-1869.
4. Chen, F. J., and H. J. Lo. 2003. Molecular mechanisms of fluoroquinolone resistance. J. Microbiol. Immunol. Infect. 36:1-9.
5. Conway, B.-A. D., V. Venu, and D. P. Speert. 2002. Biofilm formation and acyl homoserine lactone production in the Burkholderia cepacia complex. J. Bacteriol. 184:5678-5685.
6. Drabick, J. A., E. J. Gracely, G. J. Heidecker, and J. J. LiPuma. 1996. Survival of Burkholderia cepacia on environmental surfaces. J. Hosp. Infect. 32:267-276.
7. Drlica, K., and M. Malik. 2003. Fluoroquinolones: action and resistance. Curr. Top. Med. Chem. 3:249-282.
8. Drlica, K., and X. Zhou. 1997. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 61:377-392.
9. Gillespie, S. H., S. Basu, A. L. Dickens, D. M. O'Sullivan, and T. D. McHugh. 2005. Effect of subinhibitory concentrations of ciprofloxacin on Mycobacterium fortuitum mutation rates. J. Antimicrob. Chemother. 56:344-348.
10. Gillespie, S. H., L. L. Voelker, J. E. Ambler, C. Traini, and A. Dickens. 2003. Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation. Microb. Drug Resist. 9:17-24.
11. Gillespie, S. H., L. L. Voelker, and A. Dickens. 2002. Evolutionary barriers to quinolone resistance in Streptococcus pneumoniae. Microb. Drug Resist. 8:79-84.
12. Gocke, E. 1991. Mechanism of quinolone mutagenicity in bacteria. Mutat. Res. 248:135-143.
13. Hooper, D. C. 2003. Mechanisms of quinolone resistance, p. 41-67. In D. C. Hooper and E. Rubenstein (ed.), Quinolone antimicrobial agents. ASM Press, Washington, DC.
14. Isles, A., I. Maelusky, M. Corey, R. Gold, C. Prober, P. Fleming, and H. Levison. 1984. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J. Pediatr. 104:206-210.
15. Jenkins, C. 2005. Rifampicin resistance in tuberculosis outbreak, London, England. Emerg. Infect. Dis. 11:931-934.
16. Kugelberg, E., S. Lofmark, B. Wretlind, and D. I. Andersson. 2005. Reduction of the fitness burden of quinolone resistance in Pseudomonas aeruginosa. J. Antimicrob. Chemother. 55:22-30.
17. LiPuma, J. J. 1998. Burkholderia cepacia. Management issues and new insights. Clin. Chest Med. 19:473-486.
18. LiPuma, J. J., S. E. Dasen, D. W. Nielsen, R. C. Stern, and T. L. Stull. 1990. Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis. Lancet 336:1094-1096.
19. Luria, S., and M. Delbruck. 1943. Mutations of bacteria from virus sensitivity to virus resistance. Genetics 28:491-511.
20. Mamber, S. W., B. Kolek, K. W. Brookshire, D. P. Bonner, and J. Fung- Tomc. 1993. Activity of quinolones in the Ames Salmonella TA102 mutagenicity test and other bacterial genotoxicity assays. Antimicrob. Agents Chemother. 37:213-217.
21. Rosche, W. A., and P. L. Foster. 2000. Determining mutation rates in bacterial populations. Methods 20:4-17.
22. Sánchez, P., J. F. Linares, B. Ruiz-Diez, E. Campanario, A. Navas, F. Baquero, and J. L. Martinez. 2002. Fitness of in vitro selected Pseudomonas aeruginosa nalB and nfxB multidrug resistant mutants. J. Antimicrob. Chemother. 50:657-664.
23. Sierra, J. M., J. G. Cabeza, C. M. Ruiz, T. Montero, J. Hernandez, J. Mensa, M. Llagostera, and J. Vila. 2005. The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae. Clin. Microbiol. Infect. 11:750-758.
24. Smith, S. M., R. H. Eng, and F. T. Padberg, Jr. 1996. Survival of nosocomial pathogenic bacteria at ambient temperature. J. Med. 27:293-302.
25. Youmans, G. P., and A. S. Youmans. 1949. A method for the determination of the rate of growth of tubercle bacilli by the use of small inocula. J. Bacteriol. 58:247-255.
26. Ysern, P., B. Clerch, M. Castano, I. Gibert, J. Barbe, and M. Llagostera. 1990. Induction of SOS genes in Escherichia coli and mutagenesis in Salmonella typhimurium by fluoroquinolones. Mutagenesis 5:63-66.
27. Zhou, J., Y. Dong, X. Zhao, S. Lee, A. Amin, S. Ramaswamy, J. Domagala, J. M. Musser, and K. Drlica. 2000. Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations. J. Infect. Dis. 182:517-525.